We are the lung research center of the Leibniz Association. Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).
The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.
The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis. The aim is to improve the control and treatment of this disease.
Drug-resistant tuberculosis threatens children in low- and middle-income countries
A comprehensive global analysis reveals a marked increase in drug-resistant tuberculosis (DR-TB) among children. Girls in particular face a higher risk of death—highlighting significant gaps in diagnosis, treatment, and equitable access to healthcare.
05.06.2026
TBnet Academy 2026 in Vilnius
In the year marking the 20th anniversary of the Tuberculosis Network European Trials Group, TBnet successfully held its 12th TBnet Academy from 31 May to 3 June 2026 in Vilnius, Lithuania. The Academy once again brought together 20 outstanding young scholars from across Europe working in translational science, microbiology and clinical medicine in the fields of tuberculosis and diseases caused by non-tuberculous mycobacteria.
03.06.2026
Funding approved for innovative microfluidics project
The research group ‘Biophysics’ at the Research Center Borstel, Leibniz Lung Center (FZB) has some great news to celebrate: Last week, the “Leibniz Health Technologies” research network approved a feasibility study proposed by Dr Christian Nehls (FZB) in collaboration with Dr Anja Silge (Leibniz Institute of Photonics, IPHT) and Prof Miriam Agler-Rosenbaum (Leibniz Institute for Natural Product Research and Infection Biology, HKI).
Michael Wöhlke
FG Gruppe_en: Training
Contact
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.